Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. (MDP.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
MDP.TO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsMedexus Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.10B, a decrease of 4.18% year-over-year from $0.11B in FY2025.
Revenue trend
2025 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-03-31 | $0.11B | -$0.00B | -4.18% |
| 2024-03-31 | $0.11B | +$0.00B | +4.59% |
| 2023-03-31 | $0.11B | +$0.03B | +40.93% |
| 2022-03-31 | $0.08B | -$0.00B | -3.71% |
| 2021-03-31 | $0.08B | +$0.01B | +7.13% |
| 2020-03-31 | $0.07B | +$0.04B | +119.58% |
| 2019-03-31 | $0.03B | +$0.02B | +238.33% |
| 2018-03-31 | $0.01B | +$0.00B | +61.25% |
| 2017-03-31 | $0.01B | +$0.00B | +65.51% |
| 2016-03-31 | $0.00B | +$0.00B | +22.21% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Medexus Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Medexus Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Medexus Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MDP.TO revenue · 4 questionsMDP.TO's trailing twelve-month (TTM) revenue is $0.10B. That is a decrease of 4.18% year-over-year from $0.11B in FY2025.
▸ Source: FMP · Medexus Pharmaceuticals Inc. SEC filings · GAAP · Medexus Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026